Overview

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Status:
Completed
Trial end date:
2019-10-24
Target enrollment:
Participant gender:
Summary
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Kintor Pharmaceutical Inc,